Recently, Healthcare Executive (“E药经理人”), in collaboration with a leading independent corporate social responsibility consulting agency in China, released the results of 2024 “Chinese Pharmaceutical Listed Companies ESG Competitiveness” series ranking. The ranking aims to recognize Chinese pharmaceutical companies that serve as benchmarks in various aspects of ESG management. By virtue of its continuous efforts in sustainable development and low-carbon initiatives, China Medical System (“CMS” or the “Group”) has been selected into the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Mid-cap Stocks)” ranking for three consecutive years, and has also been included in the inaugural “Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies” ranking.
As an active practitioner of the sustainable development concept, CMS steadily responds to the United Nations Sustainable Development Goals, and promotes the deep integration of ESG governance with its macro strategies and business operations. With adherence to high standards of business ethics in its operations, the Group has established a scientific and effective risk identification and control system. CMS also persists in high-quality innovation, providing professional and quality products and services to all stakeholders. Concurrently, the Group genuinely cares for the development of its employees and the surrounding communities, undertaking activities such as charity donations, poverty alleviation, and caring for vulnerable groups. The Group has also been continuously exploring operational models with less impact on the ecological environment, actively promoting climate risk assessment, analysis, and response from the dimensions of “governance, strategy, risk management, and target planning”, so as to contribute its efforts to mitigate global climate change.
The Group’s continuous advancement of ESG management practices has gained widespread recognition from authoritative ESG rating agencies globally, with its ESG performance at the forefront of its global peer group. The Group’s MSCI ESG rating has been maintained at “AA”; the S&P Global ESG score has surpassed 95% of the participating peers worldwide, and has been included in the S&P Global Sustainability Yearbook (China) for two consecutive years; the HKQAA sustainability rating is in the top 10% of the industry; the Sino-Securities Index ESG Rating is “AA”.
Looking ahead, CMS will continue to adhere to responsible and sustainable operations, promoting the green transformation of the company and the pharmaceutical industry, and supporting humanity’s journey towards a sustainable and prosperous development path with practical actions.